Drug Development/R&D
New medicines lead to improved patient outcomes and societal benefits, but R&D is a long and costly process. Ongoing health economics research aims to find the right balance between incentivising manufacturers to innovate and ensuring affordable access for health systems.
Spotlight on OHE: Recent Awards, Publications and Presentations
12 September 2012
This post reviews selected external OHE activities and publications from the past three months.
OHE Conference on the Future of Drug Development – Register Now
5 September 2012
What will drug development look like in 10 years’ time? How will regulatory policies and the global political and social environment shape it? How might policy…
Register Now for the OHE Conference on Drug Development in 2022
14 August 2012
What will drug development look like in 10 years’ time? How will regulatory policies and the global political and social environment shape it? How might policy…
OHE Conference on Drug Development in 2022: Update
18 July 2012
OHE has added important panelists and speakers to fill out the conference programme for The Challenges and Economics of Drug Development in 2022, scheduled for 8…
Register Now for the OHE Conference on Drug Development in 2022
2 July 2012
Throughout its 50-year history, OHE has been a leader in contributing to the understanding of important trends in health care and in the life science industries,…
Register Now: OHE Lunchtime Seminar on Innovation
26 June 2012
In response to the R&D productivity crisis affecting the pharmaceutical industry, “big pharma” is seeking to source therapeutics from small and medium sized enterprises (SMEs). In…
Save the Date: Drug Development in 2022, OHE’s 50th Anniversary Conference
21 June 2012
The Economics of Drug Development in 2022 On 8 October, 2012, in celebration of its 50th anniversary, OHE will be holding an important conference to consider…
Register Now: SMEs as a Source of Innovation – OHE Lunchtime Seminar, 4 July
20 June 2012
In response to the R&D productivity crisis affecting the pharmaceutical industry, “big pharma” is seeking to source therapeutics from small and medium sized enterprises (SMEs). In…
New OHE Consulting Report Explores the Many Faces of Innovation
19 June 2012
Now available from the OHE website, this report provides a clear explanation of the complex nature of innovation in medicines. A fully revised and expanded version…